H1 2023 Financial Highlights

Highlights Consistent strong delivery on strategic roadmap Financial results H1 total-sales growth of 7.4% Growth platforms & newly acquired medicines now represent around two thirds of total sales Core operating margin of 34.0% Albireo Albireo acquisition completed in March Integration progressing well IPSEN Innovation for patient care I HIDO A Pipeline update Onivyde: SNDA accepted (U.S.) - 1L PDAC Bylvay: FDA approval (U.S.) - ALGS Palovarotene: favorable outcome from Advisory Committee (U.S.) - FOP Elafibranor: met primary endpoint (ELATIVE) - 2L PBC 2023 guidance upgraded Total-sales growth greater than 6.0%1 Core operating margin greater than 30.0%² All growth rates are at constant exchange rates. 1. Excludes anticipated adverse impact of around 3% from currencies, based on the average level of exchange rates in June 2023. 2. Excludes any potential impact of incremental investments from external-innovation transactions. Growth platforms: Dysport, Decapeptyl, Cabometyx and Onivyde; sNDA: supplemental New Drug Application; 1L: first line; PDAC: pancreatic ductal adenocarcinoma; ALGS: Alagille syndrome; FOP: fibrodysplasia ossificans progressiva; 2L: second line; PBC: primary biliary cholangitis. 6

View entire presentation